CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Editas Medicine Inc. (EDIT) on Wednesday reported a loss of $18.2 million in its second quarter. The Cambridge, Massachusetts-based company said it had ...

Shares of Editas Medicine fell after the company said it has commenced an underwritten public offering of its common stock and warrants. The stock slipped 16%, to $2.31, in premarket trading Tuesday.

Editas Medicine is a clinical-stage biotech. Pre-commercial drugmakers carry higher-than-average risk, as they routinely encounter significant clinical or regulatory roadblocks that sink their stock ...

Shares of Editas Medicine climbed after the company logged a narrower fourth-quarter loss and revenue that outperformed analyst estimates. The stock jumped 16% to $2.32 in Monday morning trading. The ...

As one of the most heavily regulated foods on the market, infant formula is subject to strict nutrition guidelines and undergoes rigorous safety and quality testing. But CR’s tests of infant formula ...

After making a pivot to in vivo gene editing medicines and dramatically reducing its head count last year, Editas Medicine has shared more clues about its future direction. Tuesday, the company said ...

Editas Medicine Inc. has nominated a lead in vivo development candidate, EDIT-401, a potential one-time therapy designed to significantly reduce LDL cholesterol (LDL-C) levels. The in vivo gene ...

To access the live webcasts (where available) of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be ...

Although it's a clinical-stage company, the biotech handily beat the consensus analyst estimate for second-quarter revenue. It whiffed mightily on earnings, but investors obviously didn't mind. 10 ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Editas Medicine Inc. (EDIT) on Tuesday reported a loss of $53.2 million in its second quarter. On a per-share basis, the Cambridge, Massachusetts-based ...